| Autor: |
Fujii T; Faculty of Laboratory Science, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Nishikawa J; Faculty of Laboratory Science, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Fukuda S; Faculty of Laboratory Science, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Kubota N; Faculty of Laboratory Science, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Nojima J; Faculty of Laboratory Science, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Fujisawa K; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Ogawa R; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Goto A; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Hamabe K; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Hashimoto S; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Wai AP; Department of Microbiology, Shimane University Faculty of Medicine, Izumo 693-8501, Japan., Iizasa H; Department of Microbiology, Shimane University Faculty of Medicine, Izumo 693-8501, Japan., Yoshiyama H; Department of Microbiology, Shimane University Faculty of Medicine, Izumo 693-8501, Japan., Sakai K; Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Suehiro Y; Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Yamasaki T; Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan., Takami T; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan. |
| Abstrakt: |
DNA methylation of both viral and host DNA is one of the major mechanisms involved in the development of Epstein-Barr virus-associated gastric carcinoma (EBVaGC); thus, epigenetic treatment using demethylating agents would seem to be promising. We have verified the effect of MC180295, which was discovered by screening for demethylating agents. MC180295 inhibited cell growth of the EBVaGC cell lines YCCEL1 and SNU719 in a dose-dependent manner. In a cell cycle analysis, growth arrest and apoptosis were observed in both YCCEL1 and SNU719 cells treated with MC180295. MKN28 cells infected with EBV were sensitive to MC180295 and showed more significant inhibition of cell growth compared to controls without EBV infection. Serial analysis of gene expression analysis showed the expression of genes belonging to the role of BRCA1 in DNA damage response and cell cycle control chromosomal replication to be significantly reduced after MC180295 treatment. We confirmed with quantitative PCR that the expression levels of BRCA2, FANCM, RAD51, TOP2A , and CDC45 were significantly decreased by MC180295. LMP1 and BZLF1 are EBV genes with expression that is epigenetically regulated, and MC180295 could up-regulate their expression. In conclusion, MC180295 inhibited the growth of EBVaGC cells by suppressing DNA repair and the cell cycle. |
